Plain language summary of first-line treatment with amivantamab-lazertinib for high-risk EGFR-positive lung cancer from the MARIPOSA study

This Plain Language Summary of Publication article (PLSP) from Future Oncology shares results from the MARIPOSA study, focusing on patients with advanced EGFR-positive lung cancer who had high-risk features linked to poor outcomes. The study compared the combination of amivantamab and lazertinib to osimertinib or lazertinib alone. In all patients, amivantamab plus lazertinib showed longer progression-free survival (23.7 vs. 16.6 months) and longer response duration than osimertinib.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA’ and was published in Annals of Oncology.

Visit ESMO using the link to read the original article.

• amivantamab
• clinical trial
• EGFR
• lay summary
• lazertinib
• non-small cell lung cancer
• plan language summary